Publication | Closed Access

Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study

MedicineImmunologyPharmacologyAdvanced Solid TumoursDoxorubicin-loaded Anti-egfr ImmunoliposomesTumor TargetingCancer TreatmentImmunotherapyOncologyPhase 1